论文部分内容阅读
用Bayesian一点法拟合心衰病人的DG个体药物动力学参数及个体化给药方案,用minitab对软件DG群体药物动力学数据进行统计学分析.以CrCL为固定效应变量,建立系列回归模型,预测心衰病人的DG个体药物动力学参数、个体化给药方案及其对映的(?)ss.结果显示CrCL与DG群体药物动力学参数存在高度的相关(P<0.001),相关系数分别为:CL=0.805,Vd=0.985,T_(1/2)=-0.517,K=0.525,D_(1.0)=0.714.并建立定量回归模型,预测DG个体药物动力学参数,预测参数与实测参数没有统计学差异,其中以Vd预测精度最好,有95%的预测值在实测值的95%置信限以内.与实测值相关系数为0.974,估计标准误差小于3.3%;其次是CL,有2/3的预测值在实测值95%置信限以内,与实测值相关系数为0.797,估计标准误差小于20%;T_(1/2)和K预测结果稍差.CrCL预测的个体化给药方案80%符合最佳个体化给药方案,且两者所对应的(?)ss没有显著性差异.
The Bayesian one-point method was used to fit the individual pharmacokinetic parameters of DG and individualized dosing regimen in patients with heart failure, and the statistical analysis of drug DG population pharmacokinetic data was performed with minitab.Clear regression model was established with CrCL as the fixed effect variable, The individual pharmacokinetic parameters, individualized dosing regimens and their enantiomer (?) Ss of DG in patients with CHF were analyzed.Results showed that there was a high correlation between the pharmacokinetic parameters of CrCL and DG (P <0.001), and the correlation coefficients were The results were as follows: CL = 0.805, Vd = 0.985, T 1/2 = - 0.517, K = 0.525, D 1.0 = 0.714 and the regression model was established to predict the individual pharmacokinetic parameters of DG, the prediction parameters and the measured parameters There is no statistical difference, of which the prediction accuracy of Vd is the best, 95% of the predicted value is within the 95% confidence limits of the measured value, and the measured value is 0.974, the estimated standard error is less than 3.3%; followed by CL, there are 2 / 3 is within 95% confidence limits of the measured value, and the correlation coefficient with the measured value is 0.797, the estimated standard error is less than 20%; T_ (1/2) and K predictors are slightly worse. 80% met the best individualized dosing regimen, and there was no significant difference between the two (?) Ss.